Novel codrugs with GABAergic activity for dopamine delivery in the brain

International Journal of Pharmaceutics

Volumn 437, Issue 1-2, 2012, Pages 221-231

  Denora, Nunzio ^a   Cassano, Tommaso ^b   Laquintana, Valentino ^a   Lopalco, Antonio ^a   Trapani, Adriana ^a   Cimmino, Concetta Stefania ^b   Laconca, Leonardo ^b   Giuffrida, Andrea ^c   Trapani, Giuseppe ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c University of Texas Health Science Center   (United States)

Author keywords

Blood brain barrier; Codrugs; Drug targeting; MDCKII MDR1 cell; Microdialysis; P glycoprotein

Indexed keywords

4 [6 CHLORO 3 [2 (DIPROPYLAMINO) 2 OXOETHYL]IMIDAZO[1,2 A]PYRIDIN 2 YL]PHENYL 3,4 DIHYDROXYPHENETHYLCARBAMIC ACID; 4 [6,8 DICHLORO 3 [2 (DIPROPYLAMINO) 2 OXOETHYL]IMIDAZOL[1,2 A]PYRIDIN 2 YL]PHENYL 3,4 DIHYDROXYPHENYLCARBAMIC ACID; BENZODIAZEPINE RECEPTOR; CARBAMIC ACID; CARBAMIC ACID DERIVATIVE; DIAZEPAM; DOPAMINE DERIVATIVE; ETHYL 2 [[4 [6 CHLORO 3 [2 (DIPROPYLAMINO) 2 OXOETHYL]IMIDAZO[1,2 A]PYRIDIN 2 YL]PHENOXY]CARBONYLAMINO] 3 (3,4 DIHYDROXYPHENYL)PROPANOIC ACID; ETHYL 2 [[4 [6,8 DICHLORO 3 [2 (DIPROPYLAMINO) 2 OXOETHYL]IMIDAZOL[1,2 A]PYRIDIN 2 YL]PHENOXY]CARBONYLAMINO] 3 (3,4 DIHYDROXYPHENYL)PROPANOIC ACID; IMIDAZOPYRIDINE DERIVATIVE; LEVODOPA; MULTIDRUG RESISTANCE PROTEIN; PRODRUG; RHODAMINE 123; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CELL MEMBRANE TRANSPORT; COVALENT BOND; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG TARGETING; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT;

1-OCTANOL; ACETAMIDES; ANIMALS; BRAIN; CATTLE; CELL MEMBRANE; CELLS, CULTURED; DOGS; DOPAMINE; DOPAMINE AGENTS; ENDOTHELIAL CELLS; LEVODOPA; MADIN DARBY CANINE KIDNEY CELLS; MALE; OXIDOPAMINE; P-GLYCOPROTEIN; PARKINSON DISEASE; PRODRUGS; RATS; RATS, WISTAR; RECEPTORS, GABA-A; RHODAMINE 123; WATER;

EID: 84866743619     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.08.023     Document Type: Article

References (49)

1. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov. Disord. 16 2001 448 458
2. A. Albert Chemical aspect of selective toxicity Nature 182 1958 421 423
3. K.L. Audus, and R.T. Borchardt Bovine brain microvessel endothelial cell monolayers as a model system for the blood-brain barrier Ann. N. Y. Acad. Sci. 507 1987 9 18
4. K.L. Audus, L. Ng, W. Wang, and R.T. Borchardt R.T. Borchardt, P.L. Smith, G. Wilson, Model Systems for Biopharmaceutical Assessment of Drug Absorption and Metabolism 1996 Plenum New York pp. 239-258
5. K.L. Audus, J.M. Rose, W. Wang, and R.T. Borchardt Brain microvessel endothelial cell culture systems W. Pardridge, An Introduction to the Blood-brain Barrier: Methodology and Biology 1998 Cambridge University Cambridge 86 93
6. A. Berson, V. Descatoire, A. Sutton, D. Fau, B. Maulny, N. Vadrot, G. Feldmann, B. Berthon, T. Tordjmann, and D. Pessayre Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation J. Pharmacol. Exp. Ther. 299 2001 793 800
7. P. Casellas, S. Galiegue, and A.S. Basile Peripheral benzodiazepine receptors and mitochondrial function Neurochem. Int. 40 2002 475 486
8. T. Cassano, S. Gaetani, M.G. Morgese, T. Macheda, L. Laconca, P. Dipasquale, J. Taltavull, T.S. Shippenberg, V. Cuomo, and G. Gobbi Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion Neurochem. Res. 34 2009 1417 1426
9. M.A. Cenci Dopamine dysregulation of movement control in L-DOPA induced dyskinesia Trends Neurosci. 30 2007 236 243
10. D.E. Clark Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena 2. Prediction of blood-brain barrier penetration J. Pharm. Sci. 88 1999 815 821
11. D.E. Clark Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena 1. Prediction of intestinal absorption J. Pharm. Sci. 88 1999 807 814
12. A. Daniele, A. Albanese, G. Gainotti, B. Gregari, and P. Bartolomeo Zolpidem in Parkinson's disease Lancet 349 1997 1222 1223
13. N. Das, M. Dhanawat, B. Dash, R.C. Nagarwal, and S.K. Shrivastava Codrug: an efficient approach for drug optimization Eur. J. Pharm. Sci. 41 2010 571 588
14. M. de Candia, P. Fossa, S. Cellamare, L. Mosti, A. Carotti, and C. Altomare Insights into structure-activity relationships from lipophilicity profiles of pyridin-2(1H)-one analogs of the cardiotonic agent milrinone Eur. J. Pharm. Sci. 26 2005 78 86
15. E. De Giglio, A. Trapani, D. Cafagna, L. Sabbatini, and S. Cometa Dopamine-loaded chitosan nanoparticles: formulation and analytical characterization Anal. Bioanal. Chem. 400 2011 1997 2002
16. N. Denora, V. Laquintana, A. Lopedota, M. Serra, L. Dazzi, G. Biggio, D. Pal, A.K. Mitra, A. Latrofa, G. Trapani, and G. Liso Novel L-dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety Pharm. Res. 24 2007 1309 1324
17. N. Denora, V. Laquintana, M.G. Pisu, R. Dore, L. Murru, A. Latrofa, G. Trapani, and E. Sanna 2-Phenyl-imidazo[1,2-a]pyridine compounds containing hydrophilic groups as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity and electrophysiological studies J. Med. Chem. 51 2008 6876 6888
18. N. Denora, A. Trapani, V. Laquintana, A. Lopedota, and G. Trapani Recent advances in medicinal chemistry and pharmaceutical technology-strategies for drug delivery to the brain Curr. Top. Med. Chem. 9 2009 182 196
19. N. Denora, V. Laquintana, A. Trapani, A. Lopedota, A. Latrofa, J.M. Gallo, and G. Trapani Translocator protein (TSPO) ligand-Ara-c (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential Mol. Pharm. 6 2010 2255 2269
20. R. Deumens, A. Blokland, and J. Prickaerts Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of nigrostriatal pathway Exp. Neurol. 175 2002 303 317
21. A. Di Stefano, P. Sozio, A. Iannitelli, and L.S. Cerasa New drug delivery strategies for improbe Parkinson's disease therapy Expert Opin. Drug Deliv. 6 2009 389 404
22. S. Einmahl, A.A. Deshpande, C. Tabatabay, and R. Gurny Mucosal drug delivery intravitreal E. Mathiowitz, Encyclopedia of Controlled Drug Delivery 1999 Wiley-Interscience Publication New York 564 592
23. P. Ertl, B. Rohde, and P. Selzer Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties J. Med. Chem. 43 2000 3714 3717
24. B. Feng, J.B. Mills, R.E. Davidson, R.J. Mireles, J.S. Janiszewski, M.D. Troutman, and S.M. de Morais In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system Drug Metab. Dispos. 36 2008 268 275
25. M. Fontaine, W.F. Elmquist, and D.W. Miller Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers Life Sci. 59 1996 1521 1531
26. J. Jankovic, and C.D. Marsden Therapeutic strategies in Parkinson's disease J. Jankovic, E. Tolosa, Parkinson's Disease and Movement Disorders 1988 Urban Munich pp. 95-119
27. J. Leppanen, J. Huuskonen, T. Nevalainen, J. Gynther, H. Taipale, and T. Järvinen Design and synthesis of a novel L-dopa-entacapone codrug J. Med. Chem. 45 2002 1379 1382
28. M.D. Majewska, N.L. Harrison, R.D. Schwartz, J.L. Barker, and S.M. Paul Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor Science 232 1986 1004 1007
29. Q. Mao, and J.D. Unadkat Role of the breast cancer resistance protein (ABCG2) in drug transport AAPS J. 7 1 2005 E118 E133
30. A.R. Mehdipour, and M. Hamidi Brain drug targeting: a computational approach for overcoming blood-brain barrier Drug Discov. Today 14 2009 1030 1036
31. M.G. Morgese, T. Cassano, S. Gaetani, T. Macheda, L. Laconca, P. Dipasquale, L. Ferraro, T. Antonelli, V. Cuomo, and A. Giuffrida Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2 Neurochem. Int. 54 1 2009 56 64
32. U. Norinder, and M. Haeberlein Computational approaches to the prediction of the blood-brain distribution Adv. Drug Deliv. Rev. 54 2002 291 313
33. J.G. Nutt, and W.R. Woodward Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients Neurology 36 1986 739 744
34. W.M. Pardridge Brain Drug Targeting: The Future of Brain Drug Development 2001 Cambridge University Press Cambridge, UK
35. G. Paxinos, and C.R.R. Watson The Rat Brain in Stereotaxic Coordinates 1998 Elsevier Academic Press New York
36. J. Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Järvinen, and J. Savolainen Prodrugs: design and clinical applications Nat. Rev. Drug Discov. 7 2008 255 270
37. J. Rautio, K. Laine, M. Gynther, and J. Savolainen Prodrug approaches for CNS delivery AAPS J. 10 2008 92 102
38. M. Rodriguez, I. Morales, J.L. Gonzales-Mora, I. Gomez, M. Sabate, J.G. Dopico, M.C. Rodriguez-Oroz, and J.A. Obeso Different levodopa actions on the extracellular dopamine pools in the rat striatum Synapse 61 2007 61 71
39. J.M. Rose, S.L. Peckham, J.L. Scism, and K.L. Audus Evaluation of the role of P-glycoprotein in ivermectin uptake by primary cultures of bovine brain microvessel endothelial cells Neurochem. Res. 23 1998 203 209
40. R. Rupprecht, V. Papadopoulos, G. Rammes, T.C. Baghai, J. Fan, N. Akula, G. Groyer, D. Adams, and M. Schumacher Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders Nat. Rev. Drug Discov. 9 2010 971 988
41. P. Sozio, L.S. Cerasa, A. Abbadessa, and A. Di Stefano Designing prodrugs for the treatment of Parkinson's disease Expert Opin. Drug Discov. 7 2012 385 406
42. Q.R. Smith, and P.R. Lockman Prodrug approaches for central nervous system delivery J. Rautio, Prodrugs and Targeted Delivery 2011 Wiley-VCH Verlag GmbH Weinheim pp. 253-270
43. V. Stella, R.-T. Borchardt, M. Hageman, R. Oliyai, H. Maag, and J. Tilley Prodrugs: Challenges and Rewards 2007 AAPS Press/Springer New York
44. G. Trapani, M. Franco, A. Latrofa, A. Reho, and G. Liso Synthesis, in vitro and in vivo cytotoxicity, and prediction of the intestinal absorption of substituted 2-ethoxycarbonyl-imidazo[2,1-b]benzothiazoles Eur. J. Pharm. Sci. 14 2001 209 216
45. G. Trapani, V. Laquintana, N. Denora, A. Trapani, A. Lopedota, A. Latrofa, M. Franco, M. Serra, M.G. Pisu, I. Floris, E. Sanna, G. Biggio, and G. Liso Structure-activity relationships and effects on neuroactive steroid synthesis in a series of 2-phenylimidazo[1,2-a]pyridineacetamide peripheral benzodiazepine receptors ligands J. Med. Chem. 48 2005 292 305
46. A. Trapani, E. De Giglio, D. Cafagna, N. Denora, G. Agrimi, T. Cassano, S. Gaetani, V. Cuomo, and G. Trapani Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery Int. J. Pharm. 419 2011 1296 1307
47. G. Trapani, N. Denora, A. Trapani, and V. Laquintana Recent advances in ligand targeted therapy J. Drug Target. 20 2012 1 22
48. U. Ungerstedt Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system Acta Physiol. Scand. Suppl. 367 1971 69 93
49. C. Warren Olanow Levodopa/dopamine replacement strategies in Parkinson's disease-future directions Mov. Disord. 23 2008 S613 S622